Reading Room Production — page 185

It is aft I Safety) has NIH From: "Marrazzo, Jeanne (NIH/NIAID) [E]" < @nih.gov> To: "Selgrade, Sara (NIH/NIAID) [E]" < @nih.gov> Cc: "Auchincloss, Hugh (NIH/NIAID) [E]" < @niaid.nih.gov>, "Harper, Jill (NIH/NIAID) [E]" < @niaid.nih.gov>, "Billet, Courtney (NIH/NIAID) [E]" < @niaid.nih.gov>, NIAID OCGR Leg < @mail.nih.gov> Subject: RE: For your awareness: materials requested for Dr. Tabak Date: Thu, 30 Nov 2023 07:42:04 -0500 Importance: Normal Thanks Sara, this is a very comprehensive and helpful document. JM **************************************************** Jeanne Marrazzo, MD, MPH Director, National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 NIAID Front Office Phone Fax: From: Selgrade, Sara (NIH/NIAID) [E] @nih.gov> Sent: Wednesday, November 29, 2023 7:30 PM To: Marrazzo, Jeanne (NIH/NIAID) [E] @nih.gov> Cc: Auchincloss, Hugh (NIH/NIAID) [E] @niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] @niaid.nih.gov>; Billet, Courtney (NIH/NIAID) [E] @niaid.nih.gov>; NIAID OCGR Leg @mail.nih.gov> Subject: For your awareness: materials requested for Dr. Tabak Hello Dr. Marrazzo, NIH OLPA has asked for NIAID assistance with preparing background materials for Dr. Tabak for a potential congressional staff briefing. As you are aware, there has been recent congressional interest in certain coronavirus studies conducted at RML. It is possible that Dr. Tabak may provide a briefing on this research to staff to the House Labor-HHS Appropriations Subcommittee (Chair: Rep. Robert Aderholt, R-AL) in the coming weeks. NIH OLPA has asked us to review a draft background document for Dr. Tabak. The NIH Office of Research Services (Division of Occupational Health and Safety) has reviewed as well. The legislative team worked with DIR/RML to add information requested by OLPA and make additional NIAID edits for accuracy. The attached document with NIAID edits was reviewed by Hugh, Jill, and Courtney, and will be provided to NIH OLPA for review and potential use by Dr. Tabak. Please let me know if you have any questions. Thanks, Sara